Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
September tip sheet from Cedars-Sinai Medical Center

September tip sheet from Cedars-Sinai Medical Center

A computer algorithm did a better job than doctors at documenting "red flag" symptoms among patients with gastrointestinal disorders, a Cedars-Sinai study has found, underscoring the potential of the technology to improve patient care. [More]
Shire enters into agreement with Sanquin for CINRYZE

Shire enters into agreement with Sanquin for CINRYZE

Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. [More]
Psychiatric disorders may follow trigeminal neuralgia

Psychiatric disorders may follow trigeminal neuralgia

Patients with trigeminal neuralgia have an increased risk of later developing certain psychiatric disorders, a population-based study suggests. [More]
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. [More]
EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
New study offers first clinical recommendations for headache diagnosis in pregnant women

New study offers first clinical recommendations for headache diagnosis in pregnant women

If a pregnant woman with high blood pressure and no history of headache suddenly develops a headache that quickly gets worse, she could be at risk for pregnancy complications, including preeclampsia, which put both the mother and fetus at risk. [More]
BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. [More]
FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label. [More]
Doctors suggest tips to ensure children's safety during school sports

Doctors suggest tips to ensure children's safety during school sports

Many children return to sports such as soccer, football, cross-country and volleyball when they return to school. Physicians in the Division of Sports Medicine at Cincinnati Children's Hospital Medical Center say preparation before the first day of practice is critical in helping to reduce the risk of injury. [More]
New technology that tracks patients' eye movements may accurately measure brain injury

New technology that tracks patients' eye movements may accurately measure brain injury

New technology that tracks the eye movements of patients may be a more accurate measure of brain injury than any other diagnostic measurements currently in use, according to a study recently published in the journal Concussion. [More]
In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix. [More]
Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T. [More]
New blood test could help diagnose severity of traumatic brain injury

New blood test could help diagnose severity of traumatic brain injury

A new blood test could help emergency room doctors quickly diagnose traumatic brain injury and determine its severity. [More]
Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. [More]
Helping relieve headaches in school-aged children

Helping relieve headaches in school-aged children

As the school year approaches and begins, many parents may start to hear their children complain about headaches. [More]
Rutgers physicians use new treatments to restore teenager’s life

Rutgers physicians use new treatments to restore teenager’s life

At first, 13-year-old Christina Blumstein thought she had an ordinary headache. She and her parents were returning from a visit to Long Island in July 2014 when the pain struck. Was it a bout of carsickness? Too much screen time on her iPad? But a few hours later, back home in Old Bridge, New Jersey, her mother MaryAnn says, "Christina started screaming that somebody was stabbing her in the head with a knife." Soon afterward Christina was comatose and in an ambulance - and her life was in grave danger. [More]
Metabolic imbalance caused by radiation from wireless devices linked to many health risks

Metabolic imbalance caused by radiation from wireless devices linked to many health risks

A metabolic imbalance caused by radiation from your wireless devices could be the link to a number of health risks, such as various neurodegenerative diseases and cancer, a recent study suggests. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Study looks at impact of amyloid imaging on diagnosis, management of patients with cognitive impairment

Study looks at impact of amyloid imaging on diagnosis, management of patients with cognitive impairment

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced new data showing that knowledge of amyloid status as determined by Florbetapir F 18 Injection imaging altered diagnosis and management in the majority of patients being studied. [More]
Advertisement
Advertisement